Skip to main content

Table 1 Baseline patient characteristics

From: Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO)

Characteristic ER positive ER negative Total
  No. of patients % No. of patients % No. of patients %
No. of patients 40 76.9 12 23.1 52 100
Age, years       
  Range 42.9–82.8 59.4–82.5 42.9–82.8
  Median 70.0 67.7 69.5
FIGO stage*      52 100
  I 13 32.5 9 75.0 22 42.3
  II 6 15.0 1 8.3 7 13–5
  III 11 27.5 2 16.7 13 25.0
  IV 10 25.0 0 0 10 19.2
Grade      52 100
  Well differentiated 7 17.5 0 0 7 13.5
  Mod. differentiated 17 42.5 7 58.3 24 46.2
  Poorly differentiated 14 35.0 5 41.7 19 36.5
  Not specified 2 5.0 0 0 2 3.8
Disease status at inclusion      52 100
  Relapse 26 65 8 66.7 34 65.4
  Primary metastatic disease 14 35 4 33.3 18 34.6
Previous treatment      52 100
  Surgery alone 11 27.5 1 8.3 12 23.1
  Surgery and radiation 8 20.0 1 8.3 9 17.3
  Surgery and chemotherapy 7 17.5 3 25.0 10 19.2
  Surgery, radiation and chemotherapy 14 35.0 7 58.3 21 40.4
  1. *Stage at primary diagnosis.